新型自动化Gleason分级与分子谱算法预测前列腺癌进展的验证
一项纳入892例根治性前列腺切除术后患者的前瞻性设计回顾性研究,中位随访8年;训练队列(n=306)中Precise Post-op测试预测临床失败的C-index为0.82,验证队列(n=284)为0.77,均显著优于临床特征模型(C-index 0.70),并将58%的CAPRA-S中危患者重新分类为低危。
要点
- Precise Post-op组织检测可区分术后低危与中高危前列腺癌进展。
- 验证队列C-index 0.77,优于临床特征模型的0.70。
- 该检测将58%的CAPRA-S中危患者重新分类为低危。
核心结论
- Precise Post-op组织检测能区分术后低危与中高危前列腺癌进展,机器学习辅助的自动化Gleason分级与分子谱可提升传统分级对个体化风险的预测。
研究设计与样本
- 前瞻性设计的回顾性研究,纳入892例根治性前列腺切除术后患者,中位随访8年。
- 训练队列446例中306例纳入分析,验证队列446例中284例纳入分析。
- 排除术前接受新辅助治疗(包括雄激素剥夺、放疗或化疗)及术前转移患者。
主要发现
- 训练队列中Precise Post-op预测临床失败C-index 0.82(95%CI 0.76-0.86),HR 6.7(95%CI 3.59-12.45),p<0.00001。
- 验证队列中C-index 0.77(95%CI 0.72-0.81),HR 5.4(95%CI 2.74-10.52),p<0.00001。
- 临床特征基础模型C-index为0.70,HR为3.7。
- 该检测将58%的CAPRA-S中危患者重新分类为临床失败低危。
临床怎么用
- 用于根治性前列腺切除术后风险分层,辅助识别低危与中高危进展患者。
- 可结合CAPRA-S等临床工具,优化中危患者的个体化风险再分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative risk assessment remains an important variable in the effective treatment of prostate cancer. There is an unmet clinical need for a test with the potential to enhance the Gleason grading system with novel features that more accurately reflect a personalized prediction of clinical failure. METHODS: A prospectively designed retrospective study utilizing 892 patients, post radical prostatectomy, followed for a median of 8 years. In training, using digital image analysis to combine microscopic pattern analysis/machine learning with biomarkers, we evaluated Precise Post-op model results to predict clinical failure in 446 patients. The derived prognostic score was validated in 446 patients. Eligible subjects required complete clinical-pathologic variables and were excluded if they had received neoadjuvant treatment including androgen deprivation, radiation or chemotherapy prior to surgery. No patients were enrolled with metastatic disease prior to surgery. Evaluate the assay using time to event concordance index (C-index), Kaplan-Meier, and hazards ratio. RESULTS: In the training cohort (n = 306), the Precise Post-op test predicted significant clinical failure with a C-index of 0.82, [95% CI: 0.76-0.86], HR:6.7, [95% CI: 3.59-12.45], p < 0.00001. Results were confirmed in validation (n = 284) with a C-index 0.77 [95% CI: 0.72-0.81], HR = 5.4, [95% CI: 2.74-10.52], p < 0.00001. By comparison, a clinical feature base model had a C-index of 0.70 with a HR = 3.7. The Post-Op test also re-classified 58% of CAPRA-S intermediate risk patients as low risk for clinical failure. CONCLUSIONS: Precise Post-op tissue-based test discriminates low from intermediate high risk prostate cancer disease progression in the postoperative setting. Guided by machine learning, the test enhances traditional Gleason grading with novel features that accurately reflect the biology of personalized risk assignment.
引用
- Donovan MJ, Fernandez G, Scott R, et al. Development and validation of a novel automated Gleason grade and molecular profile that define a highly predictive prostate cancer progression algorithm-based test. Prostate Cancer Prostatic Dis. 2018. PMID: 30087426. doi:10.1038/s41391-018-0067-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。